Purified recombinant EBV desoxyribonuclease in serological diagnosis of nasopharyngeal carcinoma

✍ Scribed by Marie Claude Stolzenberg; Samira Debouze; Mun Ng; Jonathan Sham; Damon Choy; Abdelmadjid Bouguermouh; K. H. Chan; Tadamasa Ooka

• Book ID: 102651274
• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: French
• Weight: 645 KB
• Volume: 66
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19960503)66:3<337::aid-ijc12>3.0.co;2-8

✦ Synopsis

To evaluate applications of highly purified recombinant EBV DNAase in the diagnosis and prognosis of NPC, we tested sera from patients with NPC, other EBV-associated diseases and EBV-seropositive and -seronegative healthy subjects by immunoblotting and DNAase inhibitory assay. The results were compared with those obtahed by the conventional immunduorercence assays against the EBV-specified earfy antigens and capsid antigens. The antiganic specificity of the imrnunoblotting assay for IgG antibody against the viral enzyme, but not that for the IgA antibody, was correlated with DNAase-inhibitory activity of the sera and their titers of IgG antibodies against the viral early antigens. Purified IgA as well as I from NPC sera highly purified viral DNase has increased the sensitivity of detection of the corresponding antibodies by immunoblotting, with the IgG antibody being detected in all but one, and IgA antibody in all but 2. of the 174 NPC sera tested. The IgG antibody was also commonly detected in the other groups of control sera, while the IgA antibody was detected in about I096 of African Burkitt's lymphoma and Algerian Hodgkin's lymphoma patients and less than 3% of the other control subjects. These results suggest that IgA antibody against recombinant EBV DNAase may be useful in the diagnosis of NPC, but the level of this antibody did not appear to be related to clinical stages of this cancer.